The Other Way In
The main viral receptor is not the only way in. Blocking one entry route does not necessarily close the other, which is part of why a single-target antiviral has been so hard to make work here.
In depth
A second surface protein cardiotropic viruses use to reach the heart muscle cell.
What drives it
Coxsackievirus B3 increases it.
10.3390/v13050718 — the second door. The heart's viral receptor is not alone — cardiotropic viruses also use decay-accelerating factor (daf/CD55) alongside the coxsackie-adenovirus receptor. An agent that blocks one doorway has not necessarily closed the other. doi 10.3390/v13050718
What it drives
It increases Heart muscle inflammation.
The second door. The heart's viral receptor is not alone — cardiotropic viruses also use decay-accelerating factor (daf/CD55) alongside the coxsackie-adenovirus receptor. An agent that blocks one doorway has not necessarily closed the other. doi 10.1038/s41568-024-00715-5 · PMC12698404
It reduces Heart muscle cell.
And blocking the second doorway works in a living animal. A soluble decoy of this receptor 'resulted in a significant decrease in myocardial lesion area and cell death and a reduction in the presence of viral RNA. All... Treatment groups had reduced INFECTIOUS CVB3 recoverable from the heart' (Lab Invest 2003;83:75-85 — Coxsackievirus B3-Associated Myocardial Pathology (soluble DAF-Fc)). Timing was everything: it worked when given 'preceding or concurrent with' infection. ⇒ the door is only worth closing before the virus is through it.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.